Ionis Pharmaceuticals Overview

  • Status
  • Public
  • Employees
  • 817
Employees
  • Stock Symbol
  • IONS
Stock Symbol
  • Investments
  • 18
  • Share Price
  • $50.24
  • (As of Wednesday Closing)

Ionis Pharmaceuticals General Information

Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Contact Information

Formerly Known As
Isis Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 2855 Gazelle Court
  • Carlsbad, CA 92010
  • United States
+1 (760) 000-0000

Ionis Pharmaceuticals Timeline

2017201820192020
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ionis Pharmaceuticals Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$50.24 $50.04 $39.32 - $66.22 $7.02B 140M 1000K $0.51

Ionis Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 5,306,832 7,112,637 6,246,340 5,953,756
Revenue 932,664 1,122,599 599,674 514,179
EBITDA 155,394 411,531 (18,839) 36,338
Net Income 73,401 294,146 273,741 346
Total Assets 3,095,701 3,233,112 2,667,784 1,322,774
Total Debt 820,664 787,526 646,720 607,477
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ionis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request a free trial

Ionis Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad
Drug Discovery
Carlsbad, CA
817 As of 2019
0000
0.000 0000-00-00
00000000000 0000

0000000

g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
000000000 00.000

000000 0

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepte
000000000000000
San Diego, CA
000 As of 0000
00000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ionis Pharmaceuticals Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 000000000 00.000
000000 00000000000 Formerly VC-backed San Diego, CA 000 00000 000000&0
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.00 00000000 00.00
You’re viewing 5 of 45 competitors. Get the full list »

Ionis Pharmaceuticals Executive Team (15)

Name Title Board Seat Contact Info
Brett Monia Ph.D Chief Executive Officer & Board Member
Elizabeth Hougen Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Frank Bennett Ph.D Chief Scientific Officer
Hezekiah Blake Director, Corporate Development
Sanjay Bhanot Chief Medical Officer & CardioMetabolic Franchise Leader
You’re viewing 5 of 15 executive team members. Get the full list »

Ionis Pharmaceuticals Board Members (10)

Name Representing Role Since
0. 00000 00000000 00 Ionis Pharmaceuticals Board Member & Strategic Advisor 000 0000
00000 00000 00.0 Ionis Pharmaceuticals Chief Executive Officer & Board Member 000 0000
000000000 0000 00 Self Board Member 000 0000
0000 000000 Self Board Member 000 0000
000000 00000 000 Ionis Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Ionis Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ionis Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request a free trial

Ionis Pharmaceuticals Investments & Acquisitions (18)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 12-Oct-2020 000000000000000000 00000 Biotechnology 00000 00000 00.0
00000000 24-Dec-2019 00000 00000 00 0000 Biotechnology
00000000 10-Nov-2017 000000000 Drug Discovery 00000 00000 00.0
0000000 00000 0000 06-Sep-2017 00000 00000 00 00.00 Diagnostic Equipment 0. 00000 00000000 00
Dynacure 01-Oct-2016 Accelerator/Incubator 00000 Drug Discovery 00000 00000 00.0
You’re viewing 5 of 18 investments and acquisitions. Get the full list »

Ionis Pharmaceuticals Subsidiaries (1)

Company Name Industry Location Founded
00000 000000000000 Biotechnology Boston, MA 0000
To view Ionis Pharmaceuticals’s complete subsidiaries history, request access »

Ionis Pharmaceuticals Exits (8)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 04-Oct-2012 000 0000 Completed
  • 3 buyers
000000 00000000000 12-Nov-2009 00000 00000 00 0000 Completed
  • 5 buyers
0000000 0000000000 04-Mar-2009 000000000 0000 Completed
  • 2 buyers
000000 00000000000 18-Dec-2007 00000 00000 00 Completed
  • 3 buyers
Excaliard Pharmaceuticals 16-Nov-2007 Early Stage VC 000.00 Completed
  • 5 buyers
You’re viewing 5 of 8 exits. Get the full list »